The retatrutide vs semaglutide vs tirzepatide comparison starts with a basic difference in receptor activity. Retatrutide targets GIP, GLP-1, and glucagon receptors; tirzepatide targets GIP and GLP-1; semaglutide acts on GLP-1 alone. Those differences drive distinct findings on weight loss, dosing, side effects, and studied applications.
Professionals reviewing this area can explore options related to retatrutide through Medica Depot’s peptide category and, for those looking to order retatrutide online, may contact the Medica Depot team for further guidance on current research specifications.
Key Takeaways
- Retatrutide activates three receptors (GIP, GLP-1, glucagon) compared with two for tirzepatide and one for semaglutide. That mechanistic difference has so far been associated with larger average weight reductions for retatrutide in trials.
- Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management. Retatrutide is still in clinical development and has not received FDA approval for any indication.
- Dosing schedules, titration steps, and studied treatment durations differ meaningfully across the three agents. This guide covers that dimension in more depth than most three-way overviews.
About: Medica Depot is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. We offer a worry-free experience in searching for the best and most popular products on the market, like retatrutide. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, quality-assured products you may need. With Medica Depot, we prioritize serving you better to improve the patient’s quality of life.
The Three Agonist Classes at a Glance: Retatrutide vs Semaglutide vs Tirzepatide
- Semaglutide, developed by Novo Nordisk, was the first of the group to reach approval and works exclusively through the GLP-1 receptor, slowing gastric emptying and reducing appetite.
- Tirzepatide, developed by Eli Lilly and Company, added a second receptor target (GIP) to that same GLP-1 mechanism. This combination is marketed as Mounjaro for type 2 diabetes and Zepbound for weight management.
- Retatrutide, also from Eli Lilly and Company, goes a step further by adding glucagon receptor agonism to the GIP/GLP-1 combination. This makes it the first triple hormone receptor agonist to reach late-stage trials.
How Do Dosage and Duration Compare Across the Three Agents?
Dosage is one of the clearest points of differentiation between the three agents, and one of the least consistently covered elsewhere.
- Semaglutide for weight management (Wegovy) follows a five-step titration: 0.25 mg once weekly for four weeks, then 0.5 mg, 1 mg, and 1.7 mg, each held for at least four weeks. It then reaches a standard maintenance dose of 2.4 mg once weekly around week 17. A higher-dose 7.2 mg option (Wegovy HD) was added more recently for patients who tolerate 2.4 mg but require additional effect [2].
- Tirzepatide (Zepbound) starts lower, at 2.5 mg once weekly for four weeks. That low dose is intended purely for tolerability, not treatment, before increasing in 2.5 mg increments every four weeks. It moves toward a maintenance range of 5 mg, 10 mg, or 15 mg once weekly, with 15 mg as the labeled maximum.
- Retatrutide’s dosing has only been studied in trials rather than fixed into an approved label. Phase 2 work evaluated 1 mg, 4 mg, 8 mg, and 12 mg doses over 48 weeks. The ongoing Phase 3 TRIUMPH program is assessing 4 mg, 9 mg, and 12 mg doses over roughly 80 weeks [1][5].
Across all three agents, dose escalation is typically paired with routine blood test monitoring, including lipid panels, HbA1c, and renal function, to track tolerability and metabolic response as the dose increases.
How Do the Mechanisms of Retatrutide, Semaglutide, and Tirzepatide Differ?
The difference between retatrutide and tirzepatide, and between both and semaglutide, comes down to receptor count. Semaglutide is a synthetic analogue of human GLP-1, engineered for a longer half-life so it can be dosed weekly rather than mimicking the native hormone’s minutes-long action.
Tirzepatide is a single molecule engineered to activate both the GIP and GLP-1 receptors, a design intended to combine GLP-1’s appetite-suppressing effect with GIP’s role in insulin sensitivity and fat metabolism. Retatrutide extends the same unimolecular-peptide approach one step further. It is a synthetic peptide, identified in trials as LY3437943, engineered to activate GIP, GLP-1, and glucagon receptors simultaneously [1].
The glucagon arm is the key structural difference: it raises energy expenditure and contributes to the liver-fat effects that set retatrutide apart from the appetite and insulin-sensitivity actions shared across all three agents.
| Retatrutide | Tirzepatide | Semaglutide | |
| Receptor targets | GIP + GLP-1 + glucagon | GIP + GLP-1 | GLP-1 only |
| Developer | Eli Lilly and Company | Eli Lilly and Company | Novo Nordisk |
| Agonist class | Triple hormone receptor agonist | Dual agonist | Single (GLP-1) agonist |
What Does Clinical Research Show for Weight Loss Across the Three Agents?
Efficacy comparisons need to be read carefully. Retatrutide’s numbers come from ongoing trials, while semaglutide’s and tirzepatide’s come from approved-drug clinical evidence already reflected in their FDA labels.
In its Phase 2 obesity trial, retatrutide produced average weight loss of up to 24.2% at 48 weeks on the 12 mg dose [1]. Topline Phase 3 TRIUMPH-1 results in adults with obesity or overweight without type 2 diabetes reported a mean weight loss of 28.3% at 80 weeks on the 12 mg dose under the efficacy estimand, with 45.3% of participants reaching at least 30% total weight loss. A weight-loss figure of roughly 30.3% was observed only in the extended 104-week cohort of participants with a baseline BMI of 35 or higher, not as the overall 80-week average [5]. Companion TRIUMPH trials in populations with knee osteoarthritis, cardiovascular disease, and type 2 diabetes reported weight loss in the low-to-high 20% range depending on comorbidity burden [5].
For comparison, semaglutide’s pivotal STEP-1 trial documented average weight loss of roughly 15% at 68 weeks in adults without diabetes, the basis for Wegovy’s original approval. The more recent STEP UP program supporting the 7.2 mg Wegovy HD dose reported mean weight loss of approximately 20.7% at 72 weeks, extending the effective range of semaglutide-based weight loss into territory previously associated only with dual-agonist therapies [2].
Tirzepatide’s SURMOUNT-1 trial reported weight loss ranging from about 15% at the 5 mg maintenance dose to nearly 21% at 15 mg over 72 weeks, the basis for Zepbound’s approval.
Retatrutide’s diabetes-specific data from the Phase 3 TRANSCEND-T2D program show weight loss of up to roughly 17% alongside meaningful HbA1c reductions, though this remains trial-stage rather than approved-drug evidence [5].
Where Do the Benefits and Side Effects Overlap, and Where Do They Diverge?
The three agents share a broadly similar side-effect profile, largely tied to their overlapping GLP-1 activity. The most commonly reported effects are nausea, vomiting, diarrhea, constipation, and decreased appetite. These are typically most pronounced during dose escalation and ease at a stable maintenance dose.
For all three agents, gastrointestinal side effects are usually what determine how quickly the dose can be increased. Tirzepatide, sold as Zepbound, is currently the only one approved by the FDA for moderate-to-severe obstructive sleep apnea in adults with obesity. In the SURMOUNT-OSA trial, participants taking tirzepatide had significantly fewer breathing interruptions during sleep than those taking placebo [4].
Semaglutide showed a related but distinct benefit in the STEP 9 trial, where adults with obesity and knee osteoarthritis reported substantial relief from osteoarthritis pain, measured by significantly greater reductions in WOMAC pain scores on semaglutide than on placebo. This is not currently an FDA-approved indication [3].
In the Phase 3 TRIUMPH-4 trial in people with obesity and knee osteoarthritis, retatrutide was linked to meaningful reductions in osteoarthritis pain alongside significant weight loss. As with the sleep-apnea-focused TRIUMPH study, these findings come from an investigational compound rather than an approved treatment [5].
All three agents also carry class-related considerations around thyroid C-cell tumors observed in rodent studies. Researchers evaluating these compounds should factor a patient’s personal and family history of medullary thyroid carcinoma into any protocol design.
FDA Approval Status: Where Does Each Agent Stand?
Semaglutide has the longest approval history of the three. It was first approved as Ozempic for type 2 diabetes in 2017, followed by Wegovy for chronic weight management in 2021, with the 7.2 mg Wegovy HD dose and an oral Wegovy option added more recently [2]. Tirzepatide followed a similar path: Mounjaro for type 2 diabetes in 2022, then Zepbound for weight management in 2023, and Zepbound for obstructive sleep apnea in December 2024 [4].
Retatrutide is still in clinical trials and has not been approved by the FDA for any indication. Eli Lilly’s TRIUMPH Phase 3 program is evaluating retatrutide across obesity, knee osteoarthritis, and sleep apnea, with a companion TRANSCEND program for type 2 diabetes and a SYNERGY program for MASLD/MASH. A regulatory submission is expected to follow as additional Phase 3 readouts are completed through 2026 and beyond [5].
Does the Comparison Extend to Cholesterol and Cardiovascular Outcomes?
Lipid and cardiovascular data add another layer to the retatrutide vs semaglutide vs tirzepatide comparison. In Phase 2 trials, retatrutide improved fasting lipid profiles, including meaningful reductions in LDL cholesterol, triglycerides, and VLDL cholesterol. This was alongside marked reductions in liver fat in a dedicated substudy of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) [1][6].
Tirzepatide has shown similar triglyceride reductions across its program, and semaglutide (Wegovy) carries an FDA-approved indication for MACE risk reduction in adults with established cardiovascular disease and obesity or overweight, based on the SELECT trial. A dedicated cardiovascular outcomes program for retatrutide is underway within TRIUMPH, but results are not yet available.
The phase 2 lipid data begins to answer questions like “Does retatrutide lower cholesterol?”, with the MASLD substudy and the lipoprotein-subclass analyses offering more granularity than a three-way comparison of this scope can accommodate.
Which Does Research Suggest Is More Effective?
The retatrutide vs semaglutide and retatrutide vs tirzepatide comparisons point toward a pattern rather than a ranking. Trial data associate each additional receptor target with somewhat larger average weight loss, in the order semaglutide < tirzepatide < retatrutide, but semaglutide and tirzepatide have completed trials supporting FDA-approved labeling while retatrutide’s TRIUMPH Phase 3 results are still investigational.
Among researchers and clinics that consult us on this comparison, the lens that matters most is usually not headline weight-loss percentage but which comorbidity data package fits the intended research question. Semaglutide is the only one with a cardiovascular-outcomes indication, tirzepatide the only one approved for OSA, and retatrutide the only one with a mature Phase 2 MASLD dataset.
| Comparison Point | Retatrutide | Semaglutide | Tirzepatide |
| FDA status | Investigational (Phase 3) | Approved (Ozempic, Wegovy) | Approved (Mounjaro, Zepbound) |
| Maintenance dose (studied or approved) | 4–12 mg weekly (trial) | 2.4 mg weekly (7.2 mg HD option) | 5–15 mg weekly |
| Longest reported trial/label duration | ~80 weeks (Phase 3, extended cohort 104 weeks) | 72 weeks (STEP UP) | 72 weeks (SURMOUNT-1) |
| Reported weight loss (up to) | 28.3% at 12 mg (80 wk); ~30.3% in extended BMI ≥35 subgroup | ~15% (STEP-1 2.4 mg); ~20.7% (STEP UP 7.2 mg) | ~21% (SURMOUNT-1 15 mg) |
| Notable studied applications | Obesity, T2D, MASLD/MASH, knee OA, OSA | Obesity, T2D, CV risk reduction, knee OA (studied) | Obesity, T2D, OSA |
Looking to buy retatrutide online? Get in touch with our customer service representatives at Medica Depot for further guidance.
The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.
Citations
[1] Jastreboff, Ania M et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.” The New England journal of medicine vol. 389,6 (2023): 514-526. doi:10.1056/NEJMoa2301972
[2] Wharton, Sean et al. “Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.” The lancet. Diabetes & endocrinology vol. 13,11 (2025): 949-963. doi:10.1016/S2213-8587(25)00226-8
[3] Bliddal, Henning et al. “Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.” The New England journal of medicine vol. 391,17 (2024): 1573-1583. doi:10.1056/NEJMoa2403664
[4] Eli Lilly and Company. “FDA Approves Zepbound® (Tirzepatide) as the First and Only Prescription Medicine for Moderate-to-Severe Obstructive Sleep Apnea in Adults With Obesity.” Eli Lilly Investor Relations, 20 Dec. 2024. https://investor.lilly.com/news-releases/news-release-details/fda-approves-zepboundr-tirzepatide-first-and-only-prescription
[5] Eli Lilly and Company. “Lilly’s Triple Agonist, Retatrutide, Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial.” Eli Lilly Investor Relations, 21 May 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
[6] Sanyal, Arun J et al. “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.” Nature medicine vol. 30,7 (2024): 2037-2048. doi:10.1038/s41591-024-03018-2
This content was prepared and reviewed under our editorial guidelines , which govern how we source, verify, and update clinical and product information. Every claim is checked against peer-reviewed research, manufacturer documentation, or regulatory guidance before publication.
Choosing the right products starts with confidence in their authenticity. At Medica Depot, we prioritize genuine branded products, reliable sourcing, and quality you can trust. Explore our standards and learn more about how we ensure product authenticity.
